Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of hAd5-S-Fusion+N-ETSD Boost in Vaccinated Adults
NCT04845191Phase 2Withdrawn
- Sponsor
- ImmunityBio, Inc.
- Start
- Dec 2021
- Primary completion
- Dec 2021
- Modality
- Prophylactic Vaccines, DNA Vaccines
01
Overview
A Phase 2 trial of hAd5-S-Fusion + N-ETSD in coronavirus disease 2019 (COVID-19), sponsored by ImmunityBio, Inc.. Planned start Dec 2021; status: withdrawn.
02
Drugs
hAd5-S-Fusion + N-ETSD
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04845191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04845191.